Check Out What Whales Are Doing With GILD
Check Out What Whales Are Doing With GILD
Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.
资金雄厚的大型鲸鱼们明显对吉利德科学持看好态度。
Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades.
我们查看吉利德科学（纳斯达克：GILD）的期权历史后发现了9宗交易。
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.
如果我们考虑每次交易的具体情况，准确地说，44%的投资者带着看好的预期开启了交易，而44%则是看淡的。
From the overall spotted trades, 3 are puts, for a total amount of $108,977 and 6, calls, for a total amount of $345,373.
根据这些交易，共有3个看跌期权，交易总金额为108,977美元，6个看涨期权，交易总金额为345,373美元。
What's The Price Target?
目标价是多少？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Gilead Sciences, spanning the last three months.
通过评估成交量和未平仓合约量，明显可以看出主力市场关注吉利德科学55.0美元到75.0美元的价格区间，该区间涵盖过去三个月。
Analyzing Volume & Open Interest
分析成交量和未平仓合约
In today's trading context, the average open interest for options of Gilead Sciences stands at 2975.88, with a total volume reaching 106.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
在当今交易背景下，吉利德科学期权的平均未平仓合约为2975.88，总成交量达到106.00。下面的图表描绘了吉利德科学高价值交易（期权的看涨和看跌量以及未平仓合约）的进展情况，该区间位于价差走廊的55.0美元至75.0美元，时间跨度为30天。
Gilead Sciences 30-Day Option Volume & Interest Snapshot
吉利德科学30天期权成交量和未平仓合约快照
Biggest Options Spotted:
最大的期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BULLISH | 01/17/25 | $18.2 | $18.2 | $18.2 | $55.00 | $91.0K | 215 | 1 |
| GILD | CALL | TRADE | BEARISH | 06/20/25 | $10.1 | $10.05 | $10.05 | $67.50 | $66.3K | 751 | 0 |
| GILD | PUT | SWEEP | BEARISH | 07/26/24 | $1.04 | $1.0 | $1.0 | $73.00 | $55.9K | 72 | 7 |
| GILD | CALL | SWEEP | BULLISH | 06/20/25 | $10.1 | $9.9 | $10.0 | $67.50 | $54.4K | 751 | 0 |
| GILD | CALL | TRADE | BULLISH | 09/20/24 | $6.4 | $6.3 | $6.38 | $67.50 | $53.5K | 871 | 1 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 看涨 | 交易 | 看好 | 01/17/25 | $18.2 | $18.2 | $18.2 | $55.00 | 91000 美元 | 215 | 1 |
| GILD | 看涨 | 交易 | 看淡 | 06/20/25 | $10.1 | $10.05 | $10.05 | $67.50 | 成交量66.3K | 751 | 0 |
| GILD | 看跌 | SWEEP | 看淡 | 07/26/24 | $1.04 | $1.0 | $1.0 | $73.00 | $55.9K | 72 | 7 |
| GILD | 看涨 | SWEEP | 看好 | 06/20/25 | $10.1 | $9.9 | $10.0 | $67.50 | $54.4K | 751 | 0 |
| GILD | 看涨 | 交易 | 看好 | 09/20/24 | 6.4美元 | $6.3 | $6.38 | $67.50 | $53.5K | 871 | 1 |
About Gilead Sciences
关于吉利德科学
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
吉利德科学公司开发和推广治疗威胁生命的传染病的疗法，其核心产品组合主要集中在治疗艾滋病毒和乙型及丙型肝炎方面。通过收购 Corus Pharma、Myogen、CV Therapeutics、Arresto Biosciences 和 Calistoga，公司将业务口径拓展至肺部和心血管疾病以及癌症治疗领域。吉利德对 Pharmasset 的收购带来了治疗丙型肝炎药物 Sovaldi 的权利，这也是组合药物 Harvoni 的一部分，而 Kite、Forty Seven 和 Immunomedics 的收购则提高了吉利德在细胞治疗和非细胞治疗肿瘤领域中的曝光度。
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考虑到吉利德科学最近的期权历史，现在应该关注该公司的表现。我们旨在探索其当前的业绩。
Present Market Standing of Gilead Sciences
吉利德科学的目前市场情况
- Currently trading with a volume of 2,761,226, the GILD's price is down by 0.0%, now at $73.51.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 20 days.
- 目前交易量为2,761,226的吉利德科学价格下跌了0.0％，现为73.51美元。
- RSI读数表明该股目前可能接近超买水平。
- 预计发布财报还有20天。
What Analysts Are Saying About Gilead Sciences
分析师对吉利德科学的看法
3 market experts have recently issued ratings for this stock, with a consensus target price of $82.33333333333333.
3位市场专家最近对此股票发表了评级，共识目标价为82.33333333333333美元。
- An analyst from Raymond James upgraded its action to Outperform with a price target of $93.
- Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Gilead Sciences, targeting a price of $80.
- An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $74.
- 来自雷蒙德詹姆斯的分析师将其评级升级为增持，并将目标价设定为93美元。
- 维持他们的立场，来自 Baird 的分析师继续持有吉利德科学的中立评级，目标价为 80 美元。
- 来自RBC Capital的分析师已将其评级下调为板块内表现，将目标价调整为74美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.
期权交易存在较高的风险和潜在回报。精明的交易者通过不断学习、调整策略、监控多种因子并密切关注市场动态来管理这些风险。随时通过Benzinga Pro获得有关吉利德科学期权交易的实时提醒，以保持了解最新情况。